Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: A cost-effectiveness analysis to inform drug pricing.

MLA

Jiang, Yunlin, et al. “Sotorasib versus Docetaxel for Treatment of US and Chinese Patients with Advanced Non-Small-Cell Lung Cancer with KRAS p.G12C-Mutated: A Cost-Effectiveness Analysis to Inform Drug Pricing.” Medicine, vol. 102, no. 50, Dec. 2023, p. e36387. EBSCOhost, https://doi.org/10.1097/MD.0000000000036387.

APA

Jiang, Y., Zhao, M., Liu, R., & Zheng, X. (2023). Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: A cost-effectiveness analysis to inform drug pricing. Medicine, 102(50), e36387. https://doi.org/10.1097/MD.0000000000036387

Chicago

Jiang, Yunlin, Mingye Zhao, Ruolin Liu, and Xueping Zheng. 2023. “Sotorasib versus Docetaxel for Treatment of US and Chinese Patients with Advanced Non-Small-Cell Lung Cancer with KRAS p.G12C-Mutated: A Cost-Effectiveness Analysis to Inform Drug Pricing.” Medicine 102 (50): e36387. doi:10.1097/MD.0000000000036387.